Accuray Incorporated is committed to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. We strive to achieve this goal by supporting well designed clinical research in a variety of pathology specific applications.
Accuray is sponsoring several clinical studies that are currently enrolling patients; these are listed below. Click on the National Institute of Health links for complete information on each study. To contact Accuray to learn more about participating as a patient or as a clinician in any of our open clinical studies, click the e-mail link below for the appropriate study or call +1.408.789.4301 or toll free +1.888.522.3740 x4301.
Prostate
Treating low and intermediate risk prostate cancer patients with the CyberKnife System
National Institute of Health (identifier: NCT00643617) - Click here to visit the website.
To email someone with Accuray about this study, click here.
Lung
Treating inoperable early stage lung cancer with the CyberKnife System
National Institute of Health (identifier: NCT00643318) - Click here to visit the website.
To email someone with Accuray about this study, click here.
A randomized study comparing surgery to CyberKnife for operable Stage I lung cancer
National Institute of Health (identifier: NCT00840749) - Click here to visit the website.
To email someone with Accuray about this study, click here.
Liver
A randomized study treating patients with primary liver cancer (hepatocellular carcinoma) with the CyberKnife System
National Institute of Health (identifier: NCT01318200) - Click here to visit the website.
To email someone with Accuray about this study, click here.
Treating patients with liver metastases from colorectal cancer with CyberKnife
National Institute of Health (identifier: NCT01318447) - Click here to visit the website.
To email someone with Accuray about this study, click here.